The University of Chicago Header Logo

James Dignam

TitleProfessor
InstitutionUniversity of Chicago
DepartmentPublic Health Sciences
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Dignam's primary research involves the design, conduct, and analysis of cancer clinical trials, including early development (phase I), pilot efficacy and safety (phase II), and definitive evaluation (phase III) trials. He is the Executive Director of the Statistics and Data Management Center for NRG Oncology, a National Cancer Institute sponsored multi-center clinical trials group with over 500 recruitment sites in North America and beyond and over 100 active clinical trials. Dr. Dignam's methodology interests include trial monitoring and early stopping rules, competing risks, hazard function estimation, and prognostic modeling. He also has engaged in and led investigations into sociodemographic factors such as race/ethnicity and BMI/obesity on cancer prognosis and treatment response. Courses taught include introductory biostatistics, clinical trials, survival analysis, and regression modeling methods.

    Collapse Biography 
    Collapse education and training
    University of Pittsburgh, Graduate School of Public Health, PittsburghPhD05/1994Biostatistics
    Saint Xavier College, ChicagoBA05/1986Mathematics
    Collapse awards and honors
    2021 Co-recipient, Statistical Partnership Among Academe, Industry, and Government (SPAIG) Award, American Statistical Association
    2019Elected Fellow, Society for Clinical Trials
    1991Inducted Member, Delta Omega, National Public Health Honor Society

    Collapse Research 
    Collapse research activities and funding
    U10CA180822     (DIGNAM, JAMES J.)Apr 18, 2014 - Feb 29, 2032
    NIH
    NRG Oncology Statistics and Data Management Center
    Role: Principal Investigator
    R03CA099508     (DIGNAM, JAMES J.)Sep 30, 2002 - Aug 31, 2005
    NIH
    Obesity and Outcomes After Early Stage Breast Cancer
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wapnir IL, Cecchini RS, Dignam JJ, Anderson SJ, Li J, Suga JM, Brufsky AM, Hopkins JO, Zeitzer K, Lyons JA, Conlin AK, Kuerer HM, Siddique S, Vallow LA, Albain KS, Cianfrocca ME, Julian TB, Boileau JF, Mamounas EP, Wolmark N. Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial. JAMA Surg. 2026 09 01; 161(9):861-869. PMID: 42384406; PMCID: PMC13324939.
      Citations:    Fields:    
    2. Kishan AU, Sun Y, Parker CC, Sargos P, Sydes M, Chabaud S, Brihoum M, Supiot S, Latorzeff I, Guerif S, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Farrell MJ, Shoag JE, Garcia JA, Brown JR, Rettig MB, Singer AE, Baclig N, Reiter RE, Eggener S, Brisbane W, Roy S, Jia AY, Ma TM, Nickols NG, Efstathiou JA, Dignam JJ, Seiferheld WF, Pollack A, Sandler HM, Nguyen PL, Pommier P, Spratt DE. Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis. Eur Urol. 2026 Jul 28. PMID: 42521517; PMCID: PMC13602305.
      Citations:    Fields:    
    3. Kishan AU, Sun Y, Parker CC, Sargos P, Sydes MR, Chabaud S, Brihoum M, Kalbasi TR, Steinberg ML, Valle LF, Taparra K, Shoag JE, Garcia JA, Brown JR, Rettig MB, Singer AE, Reiter RE, Eggener S, Brisbane W, Roy S, Zaorsky NG, Jia AY, Ma TM, Nickols NG, Efstathiou JA, Mohamad O, Dignam JJ, Seiferheld WF, Pollack A, Sandler HM, Nguyen PL, Pommier P, Spratt DE. Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. Lancet. 2026 03 14; 407(10533):1059-1071. PMID: 41765025.
      Citations: 1     Fields:    Translation:Humans
    4. Ravi P, Kwak L, Xie W, D'Amico A, Dignam J, Fizazi K, James N, Teuff GL, Nguyen PL, Sandler H, Sartor O, Sydes MR, Sweeney CJ. Docetaxel with Androgen Deprivation and Radiotherapy in High-risk Localized Prostate Cancer: An ICECaP Individual Patient Data Meta-analysis. Eur Urol Oncol. 2025 Dec 17. PMID: 41412841.
      Citations:    Fields:    
    5. Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 09 20; 43(27):3032-3040. PMID: 40779733; PMCID: PMC12440284.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    6. Le Coent Q, Legrand C, Dignam JJ, Rondeau V. Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease-Free Survival. Biom J. 2025 08; 67(4):e70064. PMID: 40579808; PMCID: PMC12205229.
      Citations:    Fields:    Translation:Humans
    7. Hamstra DA, Dignam JJ, Bruner DW, Michaelson MD, Bachand F, Master V, Torres MA, Saylor PJ, Wallace RE, Vapiwala N, Efstathiou JA, Roach M, Rosenthal SA, Raben A, Morgan SC, Kavadi VS, Spratt DE, Michalski JM, Seiferheld W, Pugh SL, Movsas B, Sandler H. Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115). Int J Radiat Oncol Biol Phys. 2025 12 01; 123(5):1247-1258. PMID: 40712984; PMCID: PMC12833922.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    8. Burdett S, Fisher DJ, Tierney JF, Cook AD, Spratt DE, Dignam JJ, Seiferheld WF, Kishan AU, Sun Y, Chabaud S, Efstathiou JA, Parker CC, Pollack A, Sargos P, Latorzeff I, Brihoum M, Catton CN, Clarke NW, Feng FY, Karrison TG, Pommier P, Sandler HM, Sydes MR, Vale CL, DADSPORT Meta-analysis Collaboration. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol. 2025 Sep; 88(3):277-290. PMID: 40571441.
      Citations: 3     Fields:    Translation:Humans
    9. Nuño MM, Pugh SL, Ji L, Piao J, Dignam JJ, Steingrimsson JA. On the use of external controls in clinical trials. J Natl Cancer Inst Monogr. 2025 03 01; 2025(68):30-34. PMID: 39989040; PMCID: PMC11848027.
      Citations:    Fields:    Translation:Humans
    10. Mazza GL, Culakova E, Enserro DM, Dignam JJ, Unger JM. Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials. J Natl Cancer Inst Monogr. 2025 03 01; 2025(68):22-29. PMID: 39989043; PMCID: PMC11848030.
      Citations: 1     Fields:    Translation:Humans
    11. Pugh SL, Lee C, Dunn BK, Dignam JJ. The importance of patient-centered research in oncology clinical trials: motivation for the Monograph series. J Natl Cancer Inst Monogr. 2025 Mar 01; 2025(68):1-2. PMID: 39989042; PMCID: PMC11848026.
      Citations:    Fields:    
    12. Apolo A, Baumann BC, Al-Ahmadie H, Ballas L, Bangs R, Brothers K, Greenberg SC, Delacroix S, Dignam JJ, Efstathiou JA, Feldman AS, Foster JC, Hahn NM, Hall E, Hansel DE, Hoffman-Censits J, Kamat AM, Kamran SC, Khani F, Lerner SP, Lipman R, Mann B, McConkey D, McKiernan J, Rose TL, Smith AB, Tangen C, Amiri AT, Weinstock C, West PJ, Milowsky MI, Black PC. Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer. Bladder Cancer. 2025 Jan-Mar; 11(1):23523735251319185. PMID: 40034245; PMCID: PMC11863732.
      Citations:    
    13. Bao R, Hutson A, Madabhushi A, Jonsson VD, Rosario SR, Barnholtz-Sloan JS, Fertig EJ, Marathe H, Harris L, Altreuter J, Chen Q, Dignam J, Gentles AJ, Gonzalez-Kozlova E, Gnjatic S, Kim E, Long M, Morgan M, Ruppin E, Valen DV, Zhang H, Vokes N, Meerzaman D, Liu S, Van Allen EM, Xing Y. Ten challenges and opportunities in computational immuno-oncology. J Immunother Cancer. 2024 10 26; 12(10). PMID: 39461879; PMCID: PMC11529678.
      Citations: 9     Fields:    Translation:Humans
    14. Pommier P, Xie W, Ravi P, Carrie C, Dignam JJ, Feng F, Sargos P, Sommer SG, Spratt DE, Tombal B, Van Poppel H, Sweeney C. Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database. Radiother Oncol. 2024 12; 201:110532. PMID: 39278317.
      Citations: 1     Fields:    Translation:Humans
    15. Karrison T, Hu C, Dignam J. Scaling and interpreting treatment effects in clinical trials using restricted mean survival time. Clin Trials. 2025 02; 22(1):3-10. PMID: 38872319; PMCID: PMC11638402.
      Citations:    Fields:    Translation:Humans
    16. Ravi P, Xie W, Buyse M, Halabi S, Kantoff PW, Sartor O, Attard G, Clarke N, D'Amico A, Dignam J, James N, Fizazi K, Gillessen S, Parulekar W, Sandler H, Spratt DE, Sydes MR, Tombal B, Williams S, Sweeney CJ. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. Eur Urol. 2025 Feb; 87(2):217-224. PMID: 38777647; PMCID: PMC11579255.
      Citations: 2     Fields:    Translation:Humans
    17. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza D, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Rodgers JP, Sandler HM. Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2024 07 10; 42(20):2377-2381. PMID: 38759121; PMCID: PMC11377096.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    18. Polley MC, Schwartz D, Karrison T, Dignam JJ. Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils. Neuro Oncol. 2024 05 03; 26(5):796-810. PMID: 38254183; PMCID: PMC11066907.
      Citations: 4     Fields:    Translation:Humans
    19. Lee CT, Selvan K, Adegunsoye A, Strykowski RK, Parker WF, Dignam JJ, Lauderdale DS, Strek ME, Press VG. Risk Factors for Hospital Readmission in Patients With Interstitial Lung Disease. Respir Care. 2024 04 22; 69(5):586-594. PMID: 38199762; PMCID: PMC11147622.
      Citations: 1     Fields:    Translation:Humans
    20. Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 03; 10(2):271-278. PMID: 38307806; PMCID: PMC11257781.
      Citations: 2     Fields:    Translation:Humans
    21. Feng F, Miladinovic B, Zhang K, Dignam JJ, Wang D, Yu M, Sandler H. Early Endpoints in High-risk Localized Prostate Cancer: Exploratory Analysis of Three Radiation Therapy Oncology Group Phase 3 Studies. Eur Urol. 2023 09; 84(3):331-340. PMID: 37393115; PMCID: PMC10947998.
      Citations: 2     Fields:    Translation:Humans
    22. Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ, Juloori A. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654. PMID: 35753553.
      Citations: 13     Fields:    Translation:Humans
    23. Turchan WT, Cutright D, Wu T, Leng JX, Dignam JJ, Eggener SE, Liauw SL. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245. PMID: 35050703.
      Citations: 3     Fields:    Translation:Humans
    24. Griggs JJ, Bohlke K, Balaban EP, Dignam JJ, Hall ET, Harvey RD, Hecht DP, Klute KA, Morrison VA, Pini TM, Rosner GL, Runowicz CD, Shayne M, Sparreboom A, Turner S, Zarwan C, Lyman GH. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2021 06 20; 39(18):2037-2048. PMID: 33939491.
      Citations: 67     Fields:    Translation:Humans
    25. Dignam JJ. Disparities in Breast Cancer: Narrowing the Gap. J Natl Cancer Inst. 2021 04 06; 113(4):349-350. PMID: 32986842; PMCID: PMC8502427.
      Citations: 3     Fields:    Translation:Humans
    26. Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT, Bahary JP. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552. PMID: 33570548; PMCID: PMC7879385.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    27. Polley MC, Dignam JJ. Statistical Considerations in the Evaluation of Continuous Biomarkers. J Nucl Med. 2021 05 10; 62(5):605-611. PMID: 33579807; PMCID: PMC8844257.
      Citations: 24     Fields:    Translation:Humans
    28. Gensheimer MF, Yom SS, Soto N, Dignam JJ, Le QT, Machtay M, Curran WJ. Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):483-485. PMID: 32890539; PMCID: PMC7462891.
      Citations: 4     Fields:    Translation:HumansCellsPHPublic Health
    29. Pugh SL, Rodgers JP, Moughan J, Bonanni R, Boparai J, Chen RC, Dignam JJ, Bruner DW. Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures? Qual Life Res. 2021 Jan; 30(1):81-89. PMID: 32894431; PMCID: PMC7855823.
      Citations: 3     Fields:    Translation:Humans
    30. Pugh SL, Rodgers JP, Yeager KA, Chen RC, Movsas B, Bonanni R, Dignam J, Bruner DW. Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical Trials. Int J Radiat Oncol Biol Phys. 2020 11 15; 108(4):950-959. PMID: 32590048; PMCID: PMC7572717.
      Citations: 13     Fields:    Translation:Humans
    31. Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Berry D, Clarke N, Collette L, D'Amico A, Lourenco RA, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt DE, Sydes MR, Williams S, Sweeney CJ, ICECaP Working Group, Tombal B. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041. PMID: 32552276; PMCID: PMC8265328.
      Citations: 22     Fields:    Translation:Humans
    32. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 05 01; 6(5):735-743. PMID: 32215583; PMCID: PMC7189892.
      Citations: 47     Fields:    Translation:Humans
    33. Hu C, Dignam JJ. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. JCO Precis Oncol. 2019; 3. PMID: 32923854; PMCID: PMC7446374.
      Citations: 43     Fields:    
    34. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983. PMID: 31120534; PMCID: PMC6547116.
      Citations: 212     Fields:    Translation:HumansCTClinical Trials
    35. Bruner DW, Pugh SL, Lee WR, Hall WA, Dignam JJ, Low D, Swanson GP, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Nguyen PL, Pisansky TM, Chen Y, Sandler HM, Movsas B. Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 May 01; 5(5):664-670. PMID: 30763425; PMCID: PMC6459051.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    36. Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, Buyse M, Sweeney CJ, Regan MM. A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz002. PMID: 31360890; PMCID: PMC6649812.
      Citations: 45     Fields:    
    37. Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, Ling YH, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, Dignam JJ, Kerr DJ, Rosell R, Mao M, Li JB, Guo YM, Wu XY, Kong LH, Tang JH, Wu XD, Li CF, Chen JR, Ou QJ, Ye MZ, Guo FM, Han P, Wang QW, Wan DS, Li L, Xu RH, Pan ZZ, Ding PR, Written on behalf of AME Colorectal Cancer Cooperative Group. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. Int J Cancer. 2019 05 01; 144(9):2161-2168. PMID: 30521064.
      Citations: 27     Fields:    Translation:HumansCellsPHPublic Health
    38. Dignam JJ, Winter KA, Michalski J. Detecting a Survival Benefit to Dose Escalation-Reply. JAMA Oncol. 2019 01 01; 5(1):110. PMID: 30452496.
      Citations:    Fields:    Translation:Humans
    39. Beitler JJ, Switchenko JM, Dignam JJ, McDonald MW, Saba NF, Shin DM, Magliocca KR, Cassidy RJ, El-Deiry MW, Patel MR, Steuer CE, Xiao C, Hudgins PA, Aiken AH, Curran WJ, Le QT. Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx. Cancer. 2019 03 01; 125(5):704-711. PMID: 30548235; PMCID: PMC6463275.
      Citations: 9     Fields:    Translation:Humans
    40. Dignam JJ, Hamstra DA, Lepor H, Grignon D, Brereton H, Currey A, Rosenthal S, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Sandler HM. Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol. 2019 01 20; 37(3):213-221. PMID: 30526194; PMCID: PMC6338393.
      Citations: 14     Fields:    Translation:Humans
    41. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019 01 05; 393(10166):40-50. PMID: 30449625; PMCID: PMC6541928.
      Citations: 607     Fields:    Translation:Humans
    42. Polanczyk CA, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Olopade O, Debiasi M, Ziegelmann P, Filho P, Albuquerque C, Reinert T, de Azambuja E. Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Front Oncol. 2018; 8:156. PMID: 29872641; PMCID: PMC5972314.
      Citations: 16     
    43. Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Dignam JJ, Werner-Wasik M, Souhami L, Lessard N. Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):38-44. PMID: 29102648; PMCID: PMC5742545.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    44. ICECaP Working Group, Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol. 2017 09 20; 35(27):3097-3104. PMID: 28796587; PMCID: PMC5652387.
      Citations: 177     Fields:    Translation:Humans
    45. Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):296-303. PMID: 28463149; PMCID: PMC5603177.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    46. Hagar Y, Dignam JJ, Dukic V. Flexible modeling of the hazard rate and treatment effects in long-term survival studies. Stat Methods Med Res. 2017 Oct; 26(5):2455-2480. PMID: 28150523; PMCID: PMC5651995.
      Citations: 2     Fields:    Translation:Humans
    47. NRG Oncology RTOG, Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017 02 02; 376(5):417-428. PMID: 28146658; PMCID: PMC5444881.
      Citations: 277     Fields:    Translation:Humans
    48. Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461. PMID: 28011046; PMCID: PMC6044722.
      Citations: 18     Fields:    Translation:Humans
    49. Zhang Q, Freidlin B, Korn EL, Halabi S, Mandrekar S, Dignam JJ. Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials. 2017 Feb; 14(1):48-58. PMID: 27590208; PMCID: PMC5300958.
      Citations: 6     Fields:    Translation:Humans
    50. Dignam J, Pickles T, Ferrer L, Rondeau V, Jacqmin-Gadda H, Proust-Lima C. Joint modelling of longitudinal and multi-state processes: application to clinical progressions in prostate cancer. Stat Med. 2016 09 30; 35(22):3933-48. PMID: 27090611; PMCID: PMC5012926.
      Citations: 14     Fields:    Translation:Humans
    51. Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM. Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol. 2016 07 10; 34(20):2325-32. PMID: 27044935; PMCID: PMC4981980.
      Citations: 288     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    52. Polite BN, Cipriano-Steffens T, Hlubocky F, Dignam J, Ray M, Smith D, Undevia S, Sprague E, Olopade O, Daugherty C, Fitchett G, Gehlert S. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148. PMID: 26983622.
      Citations: 2     Fields:    Translation:Humans
    53. Dignam JJ, Karrison TG. Building firm foundations for therapy development. J Natl Cancer Inst. 2015 Mar; 107(3). PMID: 25710961.
      Citations: 1     Fields:    Translation:Humans
    54. Wang M, Dignam JJ, Won M, Curran W, Mehta M, Gilbert MR. Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. Neuro Oncol. 2015 Jul; 17(7):999-1006. PMID: 25688120; PMCID: PMC5654351.
      Citations: 13     Fields:    Translation:HumansCells
    55. Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 01; 33(4):332-9. PMID: 25534388; PMCID: PMC4302214.
      Citations: 58     Fields:    Translation:Humans
    56. Korn EL, Dignam JJ, Freidlin B. Assessing treatment benefit with competing risks not affected by the randomized treatment. Stat Med. 2015 Jan 30; 34(2):265-80. PMID: 25363739; PMCID: PMC4268278.
      Citations:    Fields:    Translation:Humans
    57. Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02. Clin Cancer Res. 2014 Dec 15; 20(24):6379-88. PMID: 25294917; PMCID: PMC4299458.
      Citations: 8     Fields:    Translation:Humans
    58. Han B, Yu M, Dignam JJ, Rathouz PJ. Bayesian approach for flexible modeling of semicompeting risks data. Stat Med. 2014 Dec 20; 33(29):5111-25. PMID: 25274445; PMCID: PMC4744123.
      Citations: 4     Fields:    Translation:Humans
    59. Lee M, Dignam JJ, Han J. Multiple imputation methods for nonparametric inference on cumulative incidence with missing cause of failure. Stat Med. 2014 Nov 20; 33(26):4605-26. PMID: 25043107; PMCID: PMC4190095.
      Citations: 5     Fields:    Translation:Humans
    60. Taylor JM, Dignam JJ, Sène M, Jacqmin-Gadda H, Proust-Lima C. Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation. Stat Methods Med Res. 2016 12; 25(6):2972-2991. PMID: 24847900; PMCID: PMC4676739.
      Citations: 14     Fields:    Translation:Humans
    61. Gilbert MR, Dignam J, Pugh S, Armstrong TS, Wefel JS, Aldape K, Stupp R, Hegi M, Won M, Curran WJ, Mehta MP. Reply to M.C. Chamberlain. J Clin Oncol. 2014 May 20; 32(15):1634-5. PMID: 24752060; PMCID: PMC4026583.
      Citations:    Fields:    Translation:Humans
    62. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8):699-708. PMID: 24552317; PMCID: PMC4201043.
      Citations: 1500     Fields:    Translation:HumansCTClinical Trials
    63. Hou N, Hong S, Wang W, Olopade OI, Dignam JJ, Huo D. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18; 105(18):1365-72. PMID: 24003037; PMCID: PMC3776262.
      Citations: 37     Fields:    Translation:Humans
    64. Hou N, Huo D, Dignam JJ. Prevention of colorectal cancer and dietary management. Chin Clin Oncol. 2013 Jun; 2(2):13. PMID: 25841493; PMCID: PMC4415727.
      Citations: 20     Fields:    
    65. Argos M, Rahman M, Parvez F, Dignam J, Islam T, Quasem I, K Hore S, T Haider A, Hossain Z, I Patwary T, Rakibuz-Zaman M, Sarwar G, La Porte P, Harjes J, Anton K, Kibriya MG, Jasmine F, Khan R, Kamal M, Shea CR, Yunus M, Baron JA, Ahsan H. Baseline comorbidities in a skin cancer prevention trial in Bangladesh. Eur J Clin Invest. 2013 Jun; 43(6):579-88. PMID: 23590571; PMCID: PMC3953314.
      Citations: 32     Fields:    Translation:Humans
    66. Labby ZE, Armato SG, Dignam JJ, Straus C, Kindler HL, Nowak AK. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol. 2013 Apr; 8(4):478-86. PMID: 23486268; PMCID: PMC3597989.
      Citations: 9     Fields:    Translation:Humans
    67. Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ, Bentzen SM, Okunieff P, Coleman CN, Dicker AP. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24. PMID: 23231975; PMCID: PMC3536642.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    68. Wang M, Dignam JJ, Zhang QE, DeGroot JF, Mehta MP, Hunsberger S. Integrated phase II/III clinical trials in oncology: a case study. Clin Trials. 2012 Dec; 9(6):741-7. PMID: 23180870; PMCID: PMC7099526.
      Citations: 3     Fields:    Translation:Humans
    69. Labby ZE, Nowak AK, Dignam JJ, Straus C, Kindler HL, Armato SG. Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol. 2013 Apr; 24(4):999-1005. PMID: 23144443; PMCID: PMC3603437.
      Citations: 14     Fields:    Translation:Humans
    70. Labby ZE, Armato SG, Kindler HL, Dignam JJ, Hasani A, Nowak AK. Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1728-34. PMID: 23059782; PMCID: PMC3473122.
      Citations: 8     Fields:    Translation:Humans
    71. Mamounas EP, Anderson SJ, Dignam JJ, Bear HD, Julian TB, Geyer CE, Taghian A, Wickerham DL, Wolmark N. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012 Nov 10; 30(32):3960-6. PMID: 23032615; PMCID: PMC3488269.
      Citations: 200     Fields:    Translation:Humans
    72. Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ, Vogelbaum MA, Sperduto PW, Mehta MP, Machtay M, Kattan MW. A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol. 2012 Jul; 14(7):910-8. PMID: 22544733; PMCID: PMC3379797.
      Citations: 85     Fields:    Translation:Humans
    73. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH, American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012 May 01; 30(13):1553-61. PMID: 22473167.
      Citations: 172     Fields:    Translation:Humans
    74. Dookeran KA, Dignam JJ, Holloway N, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S. Race and the prognostic influence of p53 in women with breast cancer. Ann Surg Oncol. 2012 Jul; 19(7):2334-44. PMID: 22434242; PMCID: PMC4281085.
      Citations: 4     Fields:    Translation:Humans
    75. Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):782-90. PMID: 22425219; PMCID: PMC3361528.
      Citations: 29     Fields:    Translation:Humans
    76. Ferguson MK, Dignam JJ, Siddique J, Vigneswaran WT, Celauro AD. Diffusing capacity predicts long-term survival after lung resection for cancer. Eur J Cardiothorac Surg. 2012 May; 41(5):e81-6. PMID: 22368187; PMCID: PMC3327864.
      Citations: 22     Fields:    Translation:Humans
    77. Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012 Apr 15; 18(8):2301-8. PMID: 22282466; PMCID: PMC3328633.
      Citations: 191     Fields:    Translation:Humans
    78. Lee M, Cronin KA, Gail MH, Dignam JJ, Feuer EJ. Multiple imputation methods for inference on cumulative incidence with missing cause of failure. Biom J. 2011 Nov; 53(6):974-93. PMID: 22028204.
      Citations: 3     Fields:    Translation:Humans
    79. Dignam JJ. Some additional thoughts on time-varying treatment effects in breast cancer. J Clin Oncol. 2011 Nov 20; 29(33):4469-70; author reply 4470. PMID: 22025147.
      Citations: 2     Fields:    Translation:Humans
    80. Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW, ACCENT Collaborative Group. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst. 2011 Oct 19; 103(20):1498-506. PMID: 21997132; PMCID: PMC3196480.
      Citations: 31     Fields:    Translation:Humans
    81. Bae K, Bruner DW, Baek S, Movsas B, Corn BW, Dignam JJ. Patterns of missing mini mental status exam (MMSE) in radiation therapy oncology group (RTOG) brain cancer trials. J Neurooncol. 2011 Nov; 105(2):383-95. PMID: 21603964.
      Citations: 5     Fields:    Translation:Humans
    82. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011 Mar 16; 103(6):478-88. PMID: 21398619; PMCID: PMC3107729.
      Citations: 281     Fields:    Translation:Humans
    83. Chung CH, Dignam JJ, Hammond ME, Klimowicz AC, Petrillo SK, Magliocco A, Jordan R, Trotti A, Spencer S, Cooper JS, Le QT, Ang KK. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011 Apr 01; 29(10):1326-34. PMID: 21357786; PMCID: PMC3084000.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    84. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43. PMID: 20498391; PMCID: PMC2903330.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    85. Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR, O'Connell MJ, Wolmark N, Wang SJ. Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol. 2010 May 20; 28(15):2544-8. PMID: 20406942; PMCID: PMC2881729.
      Citations: 51     Fields:    Translation:Humans
    86. Huang L, Johnson KA, Mariotto AB, Dignam JJ, Feuer EJ. Population-based survival-cure analysis of ER-negative breast cancer. Breast Cancer Res Treat. 2010 Aug; 123(1):257-64. PMID: 20130982.
      Citations: 5     Fields:    Translation:Humans
    87. Dignam JJ. Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group. J Natl Cancer Inst. 2010 Feb 24; 102(4):279-80; author reply 280-2. PMID: 20075368.
      Citations: 1     Fields:    Translation:Humans
    88. Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S. p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010 May; 17(5):1398-405. PMID: 20049641.
      Citations: 32     Fields:    Translation:Humans
    89. Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20. PMID: 19933920.
      Citations: 57     Fields:    Translation:Humans
    90. Dignam JJ, Huang L, Ries L, Reichman M, Mariotto A, Feuer E. Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts. Cancer. 2009 Nov 15; 115(22):5272-83. PMID: 19670456; PMCID: PMC2783951.
      Citations: 18     Fields:    Translation:HumansPHPublic Health
    91. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009 Sep 20; 27(27):4515-21. PMID: 19704069; PMCID: PMC2754904.
      Citations: 191     Fields:    Translation:Humans
    92. Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE, Wickerham DL, Costantino JP, Wolmark N. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009 May 20; 27(15):2466-73. PMID: 19349544; PMCID: PMC2684852.
      Citations: 159     Fields:    Translation:Humans
    93. Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009 Aug; 116(3):595-602. PMID: 18830816; PMCID: PMC2711214.
      Citations: 54     Fields:    Translation:Humans
    94. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol. 2008 Aug 20; 26(24):4027-34. PMID: 18711194; PMCID: PMC2654314.
      Citations: 109     Fields:    Translation:Humans
    95. Hall MJ, Dignam JJ, Olopade OI. Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns. 2008 Aug; 17(4):365-72. PMID: 18581219; PMCID: PMC4535811.
      Citations: 2     Fields:    Translation:Humans
    96. Dignam JJ, Dukic VM. Comments on: Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, Shen K, Han Q, Shen Z, Shao Z. Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat. 2009 Jul; 116(1):209-10. PMID: 18568398.
      Citations: 1     Fields:    Translation:Humans
    97. Bradbury AR, Ibe CN, Dignam JJ, Cummings SA, Verp M, White MA, Artioli G, Dudlicek L, Olopade OI. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008 Mar; 10(3):161-166. PMID: 18344704; PMCID: PMC4199586.
      Citations: 48     Fields:    Translation:Humans
    98. Bouman P, Meng XL, Dignam J, Dukic V. A Multiresolution Hazard Model for Multicenter Survival Studies: Application to Tamoxifen Treatment in Early Stage Breast Cancer. J Am Stat Assoc. 2007 12; 102(480):1145-1157. PMID: 25620824; PMCID: PMC4302949.
      Citations: 4     
    99. Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008 Sep; 111(1):113-20. PMID: 17932744; PMCID: PMC4535794.
      Citations: 43     Fields:    Translation:HumansCells
    100. Bradbury AR, Dignam JJ, Ibe CN, Auh SL, Hlubocky FJ, Cummings SA, White M, Olopade OI, Daugherty CK. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11. PMID: 17704419.
      Citations: 46     Fields:    Translation:Humans
    101. Dukic V, Dignam J. Bayesian Hierarchical Multiresolution Hazard Model for the Study of Time-Dependent Failure Patterns in Early Stage Breast Cancer. Bayesian Anal. 2007 May 17; 2(3):591-610. PMID: 21412443; PMCID: PMC3056202.
      Citations: 8     
    102. Dignam JJ, Wieand K, Rathouz PJ. A missing data approach to semi-competing risks problems. Stat Med. 2007 Feb 20; 26(4):837-56. PMID: 16755544.
      Citations: 4     Fields:    Translation:Humans
    103. Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer. 2007 Feb 15; 109(4):802-10. PMID: 17219443.
      Citations: 77     Fields:    Translation:Humans
    104. Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell MJ, Wolmark N. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006 Nov 15; 98(22):1647-54. PMID: 17105987.
      Citations: 152     Fields:    Translation:Humans
    105. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol. 2006 May 10; 24(14):2179-87. PMID: 16682737.
      Citations: 82     Fields:    Translation:HumansPHPublic Health
    106. Dignam JJ. The ongoing search for the sources of the breast cancer survival disparity. J Clin Oncol. 2006 Mar 20; 24(9):1326-8. PMID: 16549827.
      Citations: 3     Fields:    Translation:Humans
    107. Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C, Wickerham DL. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2006 Jun; 97(3):245-54. PMID: 16331345.
      Citations: 52     Fields:    Translation:Humans
    108. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005 Dec 01; 65(23):10692-9. PMID: 16322213.
      Citations: 76     Fields:    Translation:HumansCells
    109. Dignam JJ. Early viewing of noninferiority trials in progress. J Clin Oncol. 2005 Aug 20; 23(24):5461-3. PMID: 16027438.
      Citations: 1     Fields:    Translation:Humans
    110. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005 Jul; 89(4):771-93. PMID: 15925649.
      Citations: 50     Fields:    Translation:Humans
    111. Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Extermann M, Fox S, Orosz G, Silliman R, Cullen J, Balducci L, Breast Cancer in Older Women Research Consortium. Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. J Gen Intern Med. 2005 Jun; 20(6):487-96. PMID: 15987322; PMCID: PMC1490138.
      Citations: 29     Fields:    Translation:HumansPHPublic Health
    112. Dignam JJ, Polite B, Yothers G, Raich P, Colangelo L, O'Connell M, Wolmark N. Effect of body mass index on outcomes in patients with Dukes B and C colon cancer: An analysis of NSABP randomized trials. J Clin Oncol. 2005 Jun; 23(16_suppl):3533. PMID: 27944413.
      Citations:    
    113. Thomas CR, Wilson JW, Mamounas EP, Raich PC, Lagrange A, Dignam JJ, Wickerham DL, Nolmark N. Impact of ethnic neutropenia disparity analysis in NSABP breast trials of postoperative doxorubicin (A)/cyclophosphamide (C). J Clin Oncol. 2005 Jun; 23(16_suppl):6002. PMID: 27945117.
      Citations:    
    114. Habel LA, Dignam JJ, Land SR, Salane M, Capra AM, Julian TB. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst. 2004 Oct 06; 96(19):1467-72. PMID: 15467036; PMCID: PMC2935469.
      Citations: 30     Fields:    Translation:Humans
    115. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004 Sep 4-10; 364(9437):858-68. PMID: 15351193.
      Citations: 118     Fields:    Translation:HumansCTClinical Trials
    116. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8. PMID: 15221817.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    117. Dignam JJ, Mamounas EP. Obesity and breast cancer prognosis: an expanding body of evidence. Ann Oncol. 2004 Jun; 15(6):850-1. PMID: 15151938.
      Citations: 12     Fields:    Translation:Humans
    118. Mandelblatt JS, Schechter CB, Yabroff KR, Lawrence W, Dignam J, Muennig P, Chavez Y, Cullen J, Fahs M. Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol. 2004 Jul 01; 22(13):2554-66. PMID: 15173213.
      Citations: 21     Fields:    Translation:HumansPHPublic Health
    119. Wu TH, Pabin CN, Qin Z, Blankenstein T, Philip M, Dignam J, Schreiber K, Schreiber H. Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. J Immunol. 2004 Mar 01; 172(5):3243-51. PMID: 14978132.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    120. Bryant J, Dignam JJ. Semiparametric models for cumulative incidence functions. Biometrics. 2004 Mar; 60(1):182-90. PMID: 15032788.
      Citations: 8     Fields:    Translation:Humans
    121. Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Anderson KN, Wei MJ, Adams AJ, Hagos FG, Sveen L, Lynch HT, Weber BL, Olopade OI, Ridderstråle KK. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res. 2004 Jan 15; 10(2):499-507. PMID: 14760071.
      Citations: 39     Fields:    Translation:HumansCells
    122. Dignam JJ. The role of cancer cooperative groups within the spectrum of cancer care. Cancer Control. 2004 Jan-Feb; 11(1):55-63. PMID: 14749624.
      Citations: 3     Fields:    Translation:Humans
    123. Dignam JJ, Wieand K, Johnson KA, Fisher B, Xu L, Mamounas EP. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst. 2003 Oct 01; 95(19):1467-76. PMID: 14519753; PMCID: PMC4676737.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    124. Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA, Vokes EE. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003 Sep 17; 95(18):1370-5. PMID: 13130112.
      Citations: 65     Fields:    Translation:Humans
    125. Dignam JJ, Ye Y, Colangelo L, Smith R, Mamounas EP, Wieand HS, Wolmark N. Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials. J Clin Oncol. 2003 Feb 01; 21(3):413-20. PMID: 12560428.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    126. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N, National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002 Oct 15; 20(20):4141-9. PMID: 12377957.
      Citations: 132     Fields:    Translation:HumansCTClinical Trials
    127. Dignam J, Bryant J, Paik S. Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy. Methods Mol Biol. 2002; 184:169-89. PMID: 11889713.
      Citations:    Fields:    Translation:Humans
    128. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001 Aug; 28(4):400-18. PMID: 11498833.
      Citations: 112     Fields:    Translation:HumansCTClinical Trials
    129. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001 May 02; 93(9):684-90. PMID: 11333290.
      Citations: 136     Fields:    Translation:HumansCTClinical Trials
    130. Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001 Jan 17; 93(2):112-20. PMID: 11208880.
      Citations: 34     Fields:    Translation:Humans
    131. Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001; (30):62-6. PMID: 11773294.
      Citations: 31     Fields:    Translation:Humans
    132. Dignam JJ. Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. J Natl Cancer Inst Monogr. 2001; (30):36-43. PMID: 11773290.
      Citations: 32     Fields:    Translation:Humans
    133. Dignam JJ, Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet. 2000 Mar 04; 355(9206):848-9. PMID: 10711957.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    134. Dignam JJ. Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin. 2000 Jan-Feb; 50(1):50-64. PMID: 10735015.
      Citations: 36     Fields:    Translation:Humans
    135. Dignam JJ, Colangelo L, Tian W, Jones J, Smith R, Wickerham DL, Wolmark N. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 1999 Nov 17; 91(22):1933-40. PMID: 10564677.
      Citations: 40     Fields:    Translation:Humans
    136. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999 Aug 01; 86(3):429-38. PMID: 10430251.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    137. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12; 353(9169):1993-2000. PMID: 10376613.
      Citations: 210     Fields:    Translation:HumansCTClinical Trials
    138. Dignam JJ, Bryant J, Wieand HS, Fisher B, Wolmark N. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials. 1998 Dec; 19(6):575-88. PMID: 9875837.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    139. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998 Feb; 16(2):441-52. PMID: 9469327.
      Citations: 173     Fields:    Translation:HumansCTClinical Trials
    140. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19; 89(22):1673-82. PMID: 9390536.
      Citations: 122     Fields:    Translation:HumansCTClinical Trials
    141. Dignam JJ, Redmond CK, Fisher B, Costantino JP, Edwards BK. Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Cancer. 1997 Jul 01; 80(1):80-90. PMID: 9210712.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    142. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997 Jun 04; 89(11):776-82. PMID: 9182975.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    143. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL, Deschênes L. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996 Nov 06; 88(21):1529-42. PMID: 8901851.
      Citations: 160     Fields:    Translation:HumansCTClinical Trials
    144. Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol. 1996 Jul; 14(7):1982-92. PMID: 8683228.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    145. Anderson SJ, Costantino JP, Brown AM, Bryant JL, Cronin WM, Dignam JJ, Jones JM, Rockette HE, Wieand S. Breast cancer trials on trial: a case of conflicting ethical interests. Cancer. 1995 Oct 01; 76(7):1294-5. PMID: 8630911.
      Citations: 1     Fields:    Translation:Humans
    146. Dignam JJ, Weissfeld LA, Anderson SJ. Methods for bounding the marginal survival distribution. Stat Med. 1995 Sep 30; 14(18):1985-98. PMID: 8677399.
      Citations: 1     Fields:    
    Dignam's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (417)
    Explore
    _
    Co-Authors (47)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _